Ferrell B, Thomas J, Skendelas J, Uehara M, Sugiura T
Biomedicines. 2025; 13(1).
PMID: 39857787
PMC: 11759854.
DOI: 10.3390/biomedicines13010204.
Alyasi A, Alsaad D, Alshammary E, Abdulrahman A, Ghazwani M, Almuayrifi M
Cureus. 2025; 16(12):e76144.
PMID: 39835023
PMC: 11745421.
DOI: 10.7759/cureus.76144.
Nguyen O, Fotopoulos I, Nost T, Markaki M, Lagani V, Tsamardinos I
J Cancer Res Clin Oncol. 2024; 150(8):389.
PMID: 39129029
PMC: 11317451.
DOI: 10.1007/s00432-024-05909-w.
Guo F, Adekanmbi V, Hsu C, Berenson A, Kuo Y, Shih Y
JAMA Netw Open. 2024; 7(2):e2356078.
PMID: 38353949
PMC: 10867683.
DOI: 10.1001/jamanetworkopen.2023.56078.
Hallak A, Hallak F, Hallak Y, Hallak O, Hayson A, Tanami S
Mayo Clin Proc Innov Qual Outcomes. 2023; 7(5):476-489.
PMID: 37823000
PMC: 10562863.
DOI: 10.1016/j.mayocpiqo.2023.08.004.
Health Economic Evaluation of Cognitive Control Training for Depression: Key Considerations.
Neve de Mevergnies C, Verhaeghe N, Koster E, Baeken C, Vander Zwalmen Y, Hoorelbeke K
JMIR Ment Health. 2023; 10:e44679.
PMID: 37594847
PMC: 10474514.
DOI: 10.2196/44679.
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.
Wesevich A, Goldstein D, Paydary K, Peer C, Figg W, Ratain M
Br J Cancer. 2023; 129(9):1389-1396.
PMID: 37542109
PMC: 10628132.
DOI: 10.1038/s41416-023-02367-y.
Cost-effectiveness and willing-to-pay thresholds for vertebral augmentation of osteoporotic vertebral fractures, what are they based on: a systematic review.
Pron G, Hwang M, Nasralla M, Smith R, Cheung A, Murphy K
BMJ Open. 2023; 13(7):e062832.
PMID: 37491092
PMC: 10373718.
DOI: 10.1136/bmjopen-2022-062832.
An effectiveness-implementation hybrid trial of phone-based tobacco cessation interventions in the Lebanese primary healthcare system: protocol for project PHOENICS.
Salloum R, Romani M, Bteddini D, El-Jardali F, Lee J, Theis R
Implement Sci Commun. 2023; 4(1):72.
PMID: 37365656
PMC: 10294351.
DOI: 10.1186/s43058-023-00456-w.
Economic evaluation of robotic and laparoscopic paraesophageal hernia repair.
Panse N, Prasath V, Quinn P, Chokshi R
Surg Endosc. 2023; 37(9):6806-6817.
PMID: 37264228
DOI: 10.1007/s00464-023-10119-5.
Cost-effectiveness of surgical treatment of thumb carpometacarpal joint arthritis: a value of information study.
Yoon A, Hutton D, Chung K
Cost Eff Resour Alloc. 2023; 21(1):28.
PMID: 37127634
PMC: 10150507.
DOI: 10.1186/s12962-023-00438-8.
Older People in Emergencies; Addressing Food Insecurity, Health Status and Quality of Life: Evaluating the "365+ Days of Care" Program.
Diamantis D, Katsas K, Kastorini C, Mugford L, Dalma N, Ramizi M
Int J Environ Res Public Health. 2023; 20(7).
PMID: 37047851
PMC: 10094139.
DOI: 10.3390/ijerph20075235.
Achieving malaria testing and treatment targets for children under five in Mozambique: a cost-effectiveness analysis.
Avancena A, Miller A, Canana N, Dula J, Saifodine A, Cadrinho B
Malar J. 2022; 21(1):320.
PMID: 36344998
PMC: 9641811.
DOI: 10.1186/s12936-022-04354-9.
Sentinel lymph node biopsy for head and neck cutaneous squamous cell carcinoma using the Brigham and Women's staging system: a cost analysis.
Quinn P, Kim J, Prasath V, Panse N, Knackstedt T, Chokshi R
Arch Dermatol Res. 2022; 315(3):371-378.
PMID: 35303163
DOI: 10.1007/s00403-022-02347-x.
Cost-effectiveness of a follow-up program for older patients with heart failure: a randomized controlled trial.
Gonzalez-Guerrero J, Hernandez-Mocholi M, Ribera-Casado J, Garcia-Mayolin N, Alonso-Fernandez T, Gusi N
Eur Geriatr Med. 2021; 9(4):523-532.
PMID: 34674493
DOI: 10.1007/s41999-018-0074-y.
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Kharat A, Nelson R, Au T, Biskupiak J
J Manag Care Spec Pharm. 2021; 27(10):1367-1375.
PMID: 34595948
PMC: 10391115.
DOI: 10.18553/jmcp.2021.27.10.1367.
Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.
Kouakou C, Poder T
Eur J Health Econ. 2021; 23(2):277-299.
PMID: 34417905
DOI: 10.1007/s10198-021-01364-3.
Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration.
Omidvari A, Lansdorp-Vogelaar I, de Koning H, Meester R
PLoS One. 2021; 16(7):e0253893.
PMID: 34252090
PMC: 8274850.
DOI: 10.1371/journal.pone.0253893.
Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis.
Lazzaro C, Castagna L, Lanza F, Laszlo D, Milone G, Pierelli L
Bone Marrow Transplant. 2021; 56(8):1876-1887.
PMID: 33753907
PMC: 8338551.
DOI: 10.1038/s41409-021-01251-8.
Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients.
Nathalie L, Mulligen V, Maria W, Wilhelmina H, Pieter D
Rheumatology (Oxford). 2021; 60(12):5765-5774.
PMID: 33725091
PMC: 8645278.
DOI: 10.1093/rheumatology/keab251.
